NV40 Stock Chart & Stats
€0.29
€0.00(0.00%)
At close: 4:00 PM EDT
€0.29
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€18.82M
Enterprise Value€1.54
Total Cash (Recent Filing)€33.99M
Total Debt (Recent Filing)€1.53M
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Oct 29, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding9,452,108
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.05Price Target Upside3367.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyStrong response rates and durable treatment effects provide meaningful clinical validation for iopofosine I-131 in heavily treated patients. If replicated in confirmatory testing, these results could support differentiation, regulatory progress, and eventual adoption in a difficult-to-treat hematologic cancer setting.
Regulatory ProgressA defined confirmatory Phase III plan and accelerated-approval pathway give the lead program a clearer route toward commercialization than an early discovery-stage asset. Breakthrough Designation and an anticipated six-month review could shorten the path from validated clinical data to a potential oncology product.
Platform And Manufacturing ReadinessLong-lived ligand inventory and established finished-product infrastructure may reduce preparation time for later-stage trials and a potential launch. Reported capacity of about 100 patients weekly, with additional hot cells available for scaling, supports operational readiness if approval and isotope supply are achieved.
Bears Say
Pre-commercial Business ModelCellectar remains pre-commercial, so it has no recurring product revenue to fund research, clinical development, or corporate overhead. Persistent losses mean future value depends heavily on advancing candidates to approval and generating partnerships or sales before the current development model becomes self-sustaining.
Persistent Cash BurnContinued operating and free-cash-flow deficits require external capital while clinical programs expand. Although burn improved from 2024, ongoing dependence on financing can constrain strategic flexibility, increase funding risk during development, and leave the company exposed if capital needs rise faster than programs progress.
Clinical Execution UncertaintyThe lead program still depends on multiple site and regulatory steps before enrollment can meaningfully advance. Unclear FDA gating criteria and differing timing references create execution risk, potentially delaying the Phase III dataset and accelerated-approval submission while extending cash needs and postponing any commercial revenue.
Cellectar Biosciences News
NV40 FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was €0.28 and its highest was €0.29 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is €18.82M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Oct 29, 2026 which is in 46 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Aug 13, 2026. The company reported -€0.492 earnings per share for the quarter, missing the consensus estimate of -€0.449 by -€0.043.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.48.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 9,452,108 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -€0.492 in its last earnings report, missing expectations of -€0.449. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in DE:NV40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
NV40 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical validation for iopofosine (durable responses and high response rates including a near-80% major response in the BTKi-exposed subgroup), clear progress toward a confirmatory Phase III and an intended accelerated approval filing in 1H 2027, plus meaningful balance-sheet reinforcement from an oversubscribed financing. The company is also advancing CLR 125 and expanding its PDC platform with supporting peer-reviewed data and manufacturing readiness. Offsetting these positives are materially higher R&D costs, a wider net loss in dollar terms, timing and operational risks tied to site activation/IRB/radiopharmacy readiness, just-in-time isotope production complexities, actinium-225 supply risk for alpha programs, and potential dilution from issued warrants. Overall, the highlights (clinical data, regulatory path, financing, pipeline expansion and manufacturing preparedness) materially outweigh the operational and financing caveats.View all DE:NV40 earnings summariesNV40 Stock 12 Month Forecast
Average Price Target
€10.05
▲(3367.03% Upside)